Skip to main content

Table 1 Patients’ characteristics

From: Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study

ParameterACLFNLFp
Number of patientsn = 8n = 11 
Age [years]59 (46–68)61 (55–75)0.31
GenderMales: 6Males: 81.0
Females: 2Females: 3
Weight [kg]78 (60–81)77 (55–86)0.97
Height [cm]175 (166–180)175 (170–184)0.49
APACHE II30 (25–40)32 (20–38)0.97
SOFA16 (15–19)14 (11–19)0.44
Blood flow rate [mL*h−1]100 (100–200)100 (100–200)0.84
Dialysate rate [mL*h−1]2000 (2000–2750)2000 (2000–2000)1.0
Ultrafiltrate [mL*h−1]25 (0–138)150 (50–200)0.17
Dialysate dose [ml*kg−1*h−1]31 (23–37)26 (23–40)0.90
Patients receiving norepinephrine ≥ 0.01 µg*kg−1*min−188%73%0.60
PT [%]50 (29–61)87 (74–103)0.001
Bilirubin [mg/dL]7.4 (4.3–18.7)2.1 (0.4–8.3)0.05
Antithrombin [%]48 (22–54)71 (56–90)0.004
  1. ACLF acute-on-chronic liver failure due to liver cirrhosis, NLF patients without liver failure, APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment Score, PT prothrombin time, ns not statistically significant, data are given as median and quartiles